At Kimal, we are dedicated to supporting clinicians in reducing healthcare-associated infections and protecting patients. As a long-standing partner to the NHS, we deliver innovative solutions that help address two challenging areas of infection prevention.

For over 20 years, our TauroLock™ range has helped protect vascular catheters with its proven antimicrobial, anticoagulant, and thrombolytic properties—licensed for prophylactic use to reduce infections, occlusions, and biofilm formation.

More recently, we introduced TauroPace™, an effective solution to help prevent cardiac implantable electronic device (CIED) infections. Recognised in the BHRS 2024 standards as being “associated with a reduced risk of infection”, TauroPace™ is setting new standards in patient safety.

Together, TauroLock™ and TauroPace™ represent Kimal’s ongoing commitment to advancing infection prevention and improving outcomes for patients across the NHS.